38940-62-4

Basic information

• Product Name: 3-ACETYL-5-BROMOPYRIDINE
• Synonyms: 3-ACETYL-5-BROMOPYRIDINE;1-(5-BROMOPYRIDIN-3-YL)ETHANONE;Ethanone, 1-(5-bromo-3-pyridinyl)-;3-BROMO-5-ACETYLPYRIDINE;5-Acetyl-3-bromopyridine;1-(5-broMopyridin-3-yl)ethan-1-one;3-Acetyl-5-bromopyridine,97%;5-Bromo-3-acetylpyridine
• CAS NO: 38940-62-4
• Molecular Formula: C₇H₆BrNO
• Molecular Weight: 200.03
• EINECS: -0
• Product Categories: API intermediates;Pyridines;Heterocycle-Pyridine series
• Mol File: 38940-62-4.mol
• Article Data: 8

Chemical Properties

• Melting Point: 77-79°C
• Boiling Point: 279.321 °C at 760 mmHg
• Flash Point: 122.7 °C
• Appearance: powder
• Density: 1.534 g/cm³
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.558
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: soluble in Methanol
• PKA: 1.08±0.20(Predicted)
• BRN: 112808
• CAS DataBase Reference: 3-ACETYL-5-BROMOPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-ACETYL-5-BROMOPYRIDINE(38940-62-4)
• EPA Substance Registry System: 3-ACETYL-5-BROMOPYRIDINE(38940-62-4)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39-36/37-36
• WGK Germany: 3
• Hazardous Substances Data: 38940-62-4(Hazardous Substances Data)

Usage

Chemical Properties

Hoar or pale yellow solid

Uses

3-Acetyl-5-bromopyridine is used in the synthesis of benzimidazole CYP11B2 inhibitors. Potent and selective aldosterone inhibitors are used to treat diseases such as those resulting in the stiffening of the heart.

InChI:InChI=1/C7H6BrNO/c1-5(10)6-2-7(8)4-9-3-6/h2-4H,1H3

Upstream product

• 39620-02-5 5-bromonicotinoyl chloride 
• 105-53-3 diethyl malonate 
• 20986-40-7 ethyl 5-bromo-3-pyridinecarboxylate 
• 75-16-1 methylmagnesium bromide 
• 183608-47-1 N-methyl-N-methoxy-5-bromopyridine-3-carboxamide 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 59-67-6 nicotinic acid 
• 141-78-6 ethyl acetate 

Downstream Products

• 59936-01-5 3-Acetyl-5-bromopyridine ethylene ketal 
• 142337-95-9 5-bromo-3-ethylpyridine 
• 1103862-13-0 1-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-3-yl]-ethanone 
• 956608-45-0 N-{5-[5-(diphenylmethyleneamino)pyridin-3-yl]-1-methyl-1H-pyrazol-3-yl}acetamide 
• 641615-42-1 N¹-(4-(5-bromopyridin-3-yl)pyrimidin-2-yl)-6-methylbenzene-1,3-diamine 
• 641615-41-0 4-(5-bromopyridin-3-yl)-N-(2-methyl-5-nitrophenyl)pyrimidin-2-amine 

Relevant articles and documents

-

-

DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful for therapy or prophylaxis in a mammal, and in particular as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

AMIDE DERIVATIVE AND MEDICINE

The present invention is directed to an amide derivative having excellent BCR-ABL tyrosine kinase inhibitory activity, or a salt thereof. The present invention provides an amide derivative represented by the following general formula [1]: (wherein R1 represents -CH2-R11, etc.; R2 represents alkyl, halogen, haloalkyl, etc.; R3 represents hydrogen, etc.; Het1 represents a group of the formula [6] as above, etc.; and Het2 represents pyrimidinyl, etc.), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.